The overall objective of this project is to provide support for the performance of clinical studies of the Cancer and Leukemia Group B at the Lombardi Cancer Center at Georgetown University Medical School. The LCCCC/GUMC is an NCI-designated Comprehensive Cancer Center. Louis M. Weiner, M.D. was appointed Director of the Cancer Center on January 1, 2008. The CALGB Board of Directors approved LCCCC/GUMC as a main member institution in March, 1997. LCCCC/GUMC participates in the entire range of multimodality clinical studies including therapeutic studies, correlative science studies, and companion studies of quality of life, survivorship, and cost effectiveness analyses. LCCC faculty have been active in all three areas of CALGB activities: accrual, scientific leadership, and administrative tasks. At the present time 36 CALGB protocols are active at GUMC/LCCC. During the period from 2003-2007 622 patients have been entered onto CALGB or Intergroup trials. LCCCC/GUMC faculty are represented on 13 Committees. Three LCCCC/GUMC faculty members served as study chairs and three faculty members participated in CALGB audits. It is anticipated that LCCCC/GUMC investigators will continue their activities in the CALGB and new/young faculty members will become involved in the scientific endeavors of the group as they grow in their careers. LCCC/GUMC faculty members have been a co-author or primary author on 35 CALGB publications.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Georgetown University
Organized Research Units
United States
Zip Code
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Heist, Rebecca S; Wang, Xiaofei; Hodgson, Lydia et al. (2014) CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. J Thorac Oncol 9:214-21
Smith, Matthew R; Halabi, Susan; Ryan, Charles J et al. (2014) Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance). J Clin Oncol 32:1143-50
Du, Juan; Lopez-Verges, Sandra; Pitcher, Brandelyn N et al. (2014) CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells. Cancer Immunol Res 2:878-89
Zirpoli, Gary R; Brennan, Patrick M; Hong, Chi-Chen et al. (2013) Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat 137:903-13
Grant, Barbara W; Jung, Sin-Ho; Johnson, Jeffrey L et al. (2013) A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701. Cancer 119:3797-804
Rubenstein, James L; Hsi, Eric D; Johnson, Jeffrey L et al. (2013) Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol 31:3061-8
Smith, Sonali M; Schoder, Heiko; Johnson, Jeffrey L et al. (2013) The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance). Leuk Lymphoma 54:1405-10
Edelman, Martin J; Hodgson, Lydia; Rosenblatt, Paula Y et al. (2012) CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol 7:649-54
Romanus, Dorothy; Kindler, Hedy L; Archer, Laura et al. (2012) Does health-related quality of life improve for advanced pancreatic cancer patients who respond to gemcitabine? Analysis of a randomized phase III trial of the cancer and leukemia group B (CALGB 80303). J Pain Symptom Manage 43:205-17

Showing the most recent 10 out of 50 publications